Research programme: anthrax vaccine (third generation) - PharmAthene

Drug Profile

Research programme: anthrax vaccine (third generation) - PharmAthene

Alternative Names: Lyophilized recombinant protective antigen anthrax vaccine; Lyophilized rPA anthrax vaccine

Latest Information Update: 15 Apr 2016

Price : $50

At a glance

  • Originator Avecia
  • Developer PharmAthene
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research Anthrax

Most Recent Events

  • 13 Apr 2016 Research programme: anthrax vaccine (third generation) - PharmAthene is available for licensing as of 13 Apr 2016.
  • 11 Mar 2014 Research is ongoing USA
  • 16 Jul 2010 Pharmacodynamics data from a preclinical trial in Anthrax infections released by PharmAthene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top